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ABSTRACT During their development within the vertebrate host, Plasmodium para-
sites infect hepatocytes and red blood cells. Within these cells, parasites are sur-
rounded by a parasitophorous vacuole membrane (PVM). The PVM plays an essential
role for the interaction of parasites with their host cells; however, only a limited
number of proteins of this membrane have been identiﬁed so far. This is partially
because systematic proteomic analysis of the protein content of the PVM has been
difﬁcult in the past, due to difﬁculties encountered in attempts to separate the PVM
from other membranes such as the parasite plasma membrane. In this study, we
adapted the BioID technique to in vitro-cultivated Plasmodium berghei blood stage
parasites and utilized the promiscuous biotin ligase BirA* fused to PVM-resident ex-
ported protein 1 to biotinylate proteins of the PVM. These we further processed by
afﬁnity puriﬁcation, liquid chromatography-tandem mass spectrometry (LC-MS/MS), and
label-free quantitation, leading to a list of 61 known and candidate PVM proteins. Seven
proteins were analyzed further during blood and liver stage development. This resulted
in the identiﬁcation of three novel PVM proteins, which were the serine/threonine
protein phosphatase UIS2 (PlasmoDB accession no. PBANKA_1328000) and two
conserved Plasmodium proteins with unknown functions (PBANKA_0519300 and
PBANKA_0509000). In conclusion, our report expands the number of known PVM
proteins and experimentally validates BioID as a powerful method to screen for
novel constituents of speciﬁc cellular compartments in P. berghei.
IMPORTANCE Intracellular pathogens are often surrounded by a host-cell derived
membrane. This membrane is modiﬁed by the pathogens to their own needs and is
crucial for their intracellular lifestyle. In Plasmodium parasites, this membrane is re-
ferred to as the PVM and only a limited number of its proteins are known so far.
Here, we applied in rodent P. berghei parasites a method called BioID, which is
based on biotinylation of proximal and interacting proteins by the promiscuous bio-
tin ligase BirA*, and demonstrated its usefulness in identiﬁcation of novel PVM pro-
teins.
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Malaria is a widespread disease putting half of the world’s population at risk ofinfection and leading to nearly half a million deaths per year (1). The causative
agent of the disease is Plasmodium, a parasite transmitted by infected Anopheles
mosquitoes during a blood meal. After injection into the skin of a vertebrate host,
Plasmodium sporozoites actively enter blood vessels and reach the liver, where they
infect hepatocytes. Here they undergo a ﬁrst round of multiplication. After release from
Received 2 November 2017 Accepted 22
December 2017 Published 24 January 2018
Citation Schnider CB, Bausch-Fluck D,
Brühlmann F, Heussler VT, Burda P-C. 2018.
BioID reveals novel proteins of the Plasmodium
parasitophorous vacuole membrane. mSphere
3:e00522-17. https://doi.org/10.1128/mSphere
.00522-17.
Editor Ira J. Blader, University at Buffalo
Copyright © 2018 Schnider et al. This is an
open-access article distributed under the terms
of the Creative Commons Attribution 4.0
International license.
Address correspondence to Paul-Christian
Burda, burda@bnitm.de.
* Present address: Paul-Christian Burda,
Bernhard Nocht Institute for Tropical Medicine,
Hamburg, Germany.
Novel proteins of the Plasmodium
parasitophorous vacuole membrane identiﬁed
RESEARCH ARTICLE
Host-Microbe Biology
crossm
January/February 2018 Volume 3 Issue 1 e00522-17 msphere.asm.org 1
 o
n
 January 24, 2018 by guest
http://m
sphere.asm
.org/
D
ow
nloaded from
 
the liver, parasites repeatedly invade and multiply within red blood cells (RBCs), leading
to the symptoms of malaria. Within hepatocytes and RBCs, Plasmodium parasites reside
within a specialized compartment referred to as the parasitophorous vacuole (PV) and
are surrounded by the PV membrane (PVM), which is initially formed by invagination of
the host cell membrane (HCM) during the process of invasion (reviewed in reference 2).
The PVM is extensively remodeled by the parasite, and, as the interface between the
parasite and its host cell, it plays fundamental roles in nutrient acquisition, host cell
remodeling, waste disposal, environmental sensing, and protection from innate de-
fense mechanisms of the host cell (reviewed in reference 3). At the end of parasite
development in hepatocytes and RBCs, parasites induce disruption of the PVM and the
HCM, which is essential for their release from host cells and for propagating the
infection.
Only a limited number of PVM proteins have been identiﬁed so far, and the
functions of most of these remain elusive (reviewed in references 3 and 4). These
include the earliest known PVM protein, exported protein 1 (EXP1), which contains a
classical N-terminal signal peptide and is inserted into the PVM of blood and liver stage
parasites with its transmembrane domain, whereby the C terminus faces the host cell
cytoplasm (5–8). EXP1 was shown to be refractory to gene deletion, indicating an
essential role for asexual blood stage development as gene targeting is performed in
this stage (9). In line with its predicted glutathione S-transferase activity, EXP1 has the
ability to conjugate glutathione onto hematin in vitro (10). Furthermore, evidence was
provided that the C-terminal portion of EXP1 speciﬁcally interacts with host apolipo-
protein H and that this interaction is crucial for development of the parasite within the
liver (11). Other prominent PVM proteins are the components of the Plasmodium
translocon of exported proteins (PTEX), mediating the export of proteins into the host
cell (12), and proteins belonging to the family of the early transcribed membrane
proteins (ETRAMPs) (13).
In general, many more PVM proteins have been identiﬁed in blood stage parasites
than in liver stage parasites, where only a few PVM proteins are known so far (reviewed
in references 3 and 4). Apart from EXP1, these liver stage PVM proteins include two
members of the ETRAMP family, UIS3 and UIS4, the knockout of which leads to parasites
arrested in early liver stage development (14, 15), or the phospholipase PbPL, whose
deletion results in parasites that are impaired in rupturing the liver stage PVM during
egress from host hepatocytes (16).
A systematic proteomic analysis of the PVM’s protein composition has been difﬁcult
in the past, due to difﬁculties encountered in attempts to separate the PVM from other
membranes such as the parasite plasma membrane (PPM). In this study, we applied the
BioID technique to identify novel proteins of the Plasmodium PVM. This biochemical
approach is based on the promiscuous biotin ligase BirA*, which can be fused to a
protein of interest and, upon addition of biotin, leads to the biotinylation of proximal
and potentially interacting proteins that can be afﬁnity puriﬁed and identiﬁed by mass
spectrometry (17). Using EXP1 as the bait, we identiﬁed 61 known and candidate PVM
proteins. We further analyzed a subset of these candidates by endogenous green
ﬂuorescent protein (GFP) tagging during blood and liver stage development, leading to
the discovery of three novel PVM proteins.
RESULTS
Tagging of the PVM-resident EXP1 protein with the BirA* biotin ligase. To
identify novel proteins of the Plasmodium PVM, we adapted the BioID approach and
fused the biotin ligase BirA* to EXP1, which is a known protein of the PVM in blood and
liver stage parasites (Fig. 1A). With this aim, we generated the plasmid pL0017-CEXP1-
BirA*-V5, encoding an EXP1-BirA* fusion protein with a C-terminal V5 tag under control
of the constitutive P. berghei eef1 promoter (Fig. 1B). This vector integrates by
single-crossover homologous recombination into either the c-ssu-rRNA locus or d-ssu-
rRNA locus of P. berghei and conveys resistance to pyrimethamine. We transfected it
into blood stage schizonts of marker-free parasites expressing mCherry under the
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control of the constitutive P. berghei hsp70 promoter (16). The parental line expressing
mCherry was used as a control and is further referred to as the wild type (WT). We
obtained transgenic EXP1-BirA*-V5 parasites after drug selection and conﬁrmed suc-
cessful integration into the genome by PCR (see Fig. S1 in the supplemental material).
To investigate whether this construct is expressed in blood stages and leads to the
biotinylation of PVM proteins, we isolated the blood of mice infected with transgenic
EXP1-BirA*-V5 parasites by cardiac puncture and cultivated it in an in vitro schizont
culture for 18 h in the presence of 150 M biotin. Biotinylated proteins were visualized
by immunoﬂuorescence analysis (IFA) using ﬂuorescently labeled streptavidin. As
expected, we observed a strong streptavidin signal, which was peripherally located
around parasites and colocalized with the V5-tagged EXP1-BirA* fusion protein (Fig. 1C).
We further conﬁrmed this ﬁnding by performing Western blot analyses of EXP1-
BirA*-V5 parasites grown in the presence or absence of biotin and parental WT parasites
cultivated in the presence of biotin. We observed a substantial increase in the levels of
biotinylated proteins in lysates of EXP1-BirA*-V5 parasites grown in the presence of
biotin in comparison to the WT and no-biotin controls (Fig. 1D), where only very few
biotinylated proteins were visible. In conclusion, these data demonstrate that
EXP1-BirA*-V5 is active and biotinylates a range of target proteins at the parasite
periphery.
Identiﬁcation of novel PVM candidate proteins by mass spectrometry. To
identify the targets labeled by EXP1-BirA*-V5, we performed two independent exper-
iments, in which we subjected biotinylated proteins to afﬁnity puriﬁcation using
streptavidin-conjugated magnetic beads and analyzed them by label-free quantitative
mass spectrometry. We compared EXP1-BirA*-V5 parasites to parental WT parasites,
FIG 1 Expression of EXP1-BirA*-V5 leads to biotinylation of proteins at the parasite periphery. (A) Localization of
EXP1 within Plasmodium-infected erythrocytes. (B) Schematic representation of the expression cassette encoding
EXP1 fused to BirA* with a C-terminal V5 tag driven by the constitutive eef1 promoter. (C) IFA of EXP1-BirA*-V5
blood stage parasites grown for 18 h in the presence of biotin. Biotinylated proteins were detected by Alexa Fluor
488-labeled streptavidin (Strep; green). The cytosolic mCherry is shown in red and the V5 signal in purple. Parasite
nuclei were stained with DAPI and are displayed in blue. Scale bar, 2 m. (D) Western blot analysis of lysates from
EXP1-BirA*-V5 parasites grown for 18 h with or without biotin and WT parasites grown in the presence of biotin.
Lysates were probed with ﬂuorescently labeled streptavidin to detect biotinylated proteins. The EXP1-BirA*-V5
fusion protein is predicted to be 55 kDa (asterisk). Cytosolic mCherry detected with an anti-RFP antibody served
as a loading control.
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both of which were grown in the presence of biotin. Altogether, we identiﬁed 1,157
proteins; quantitative information could be extracted for 631 proteins, and 357 were
reliably quantiﬁed with at least two independent peptide measurements across all
samples. Proteins that were at least three times more abundant in EXP1-BirA*-V5
parasites than in WT parasites in both independent experiments, with an adjusted P
value of below 0.05 as calculated based on analysis of variance (ANOVA) models, were
considered signiﬁcantly enriched in EXP1-BirA*-V5 parasites (Fig. 2; see also Fig. S2 and
Table S1 in the supplemental material). Among these 82 proteins, we further excluded
all proteins which did not contain a signal peptide and/or at least one transmembrane
domain, resulting in a ﬁnal list of 61 candidate proteins, including several already-
identiﬁed PVM-resident proteins, such as all components of the PTEX complex
(PTEX150, Hsp101, PTEX88, TRX2, and EXP2) and two members of the ETRAMP family
(Fig. 3; see also Table S2).
Localization of selected candidates by endogenous GFP tagging. Among the
proteins identiﬁed by mass spectrometry, we selected seven proteins and determined
their localization by C-terminal GFP tagging. We concentrated on candidates that had
not yet been localized in P. berghei and P. falciparum at the time of analysis, most of
which were annotated as proteins with unknown function. Each corresponding gene
was targeted using the pOB277 vector (18) that integrates by single-crossover homol-
ogous recombination into the endogenous locus, leading to expression of a GFP-
tagged version of the protein under the control of its endogenous promoter (Fig. S3A).
Successful integration into the desired locus was conﬁrmed by PCR (Fig. S3B), and
transgenic blood stage parasites were analyzed live by ﬂuorescence microscopy. We
focused our analysis on schizonts and free merozoites, as these stages allow
discrimination between putative PVM, PV, and PPM localizations. We did not
FIG 2 Identiﬁcation of PVM candidates by quantitative mass spectrometry. A volcano plot depicting quantiﬁed
proteins is shown. The x axis shows the average fold change (log2) in protein abundance in EXP1-BirA*-V5 samples
in comparison to WT controls, and the y axis shows the average adjusted (adj.) P value; the data for both were
determined on the basis of results from two independent experiments. Proteins meeting the selection criteria (for
details, see the main text) and considered signiﬁcantly enriched in EXP1-BirA*-V5 parasites are displayed in yellow.
The bait protein (EXP1; PBANKA_0926700) and candidates selected for further localization studies are highlighted
in red. For a complete list of all identiﬁed proteins, see Table S1; for a Venn diagram showing the overlap of the
data from the two independent experiments, see Fig. S2. Proteins signiﬁcantly enriched in EXP1-BirA*-V5 parasites
and containing a signal peptide and/or at least one transmembrane domain are displayed and further described
in Fig. 3 (see also Table S2).
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FIG 3 PVM candidates with a signal peptide and/or at least one transmembrane domain. Data corresponding to PVM or PV
localization of candidate proteins in P. berghei and P. falciparum determined on the basis of this work and published studies that used
electron and/or ﬂuorescence microscopy techniques for protein localization are indicated. Proteins that showed at least partial PVM
localization during blood and/or liver stage development in P. berghei or P. falciparum are indicated in green, while proteins with at
least partial PV localization and no further PVM localization are shown in blue. Candidate proteins analyzed in this study are
highlighted in bold. P. falciparum orthologs were identiﬁed in http://plasmodb.org/plasmo/, and, in some cases, synteny was used as
a further indicator to support orthology (indicated by asterisks). Candidates are ordered by increasing average P values. For details
regarding localizations (including references) see Table S2. ID, identiﬁer; SP, signal peptide. TM, number of transmembrane domains.
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perform further colocalization experiments in the blood stage, as discrimination of
PVM, PV, and PPM proteins in this stage by IFA is very difﬁcult to achieve, due to
the close proximity of the PVM and the PPM (3). Instead, we decided to include liver
stage parasites in our analysis, where such discrimination by IFA is possible. The
cytomere stage is particularly suited to localization studies, since parasites are very
large at that time point and the PPM has already started to invaginate (19), allowing
a clear differentiation between a potential PVM and PV/PPM localization. We
therefore concentrated on fully developed cytomere liver stage parasites, which
were ﬁxed and stained with an antiserum against EXP1 to perform colocalization
analysis by confocal microscopy.
Candidate proteins with PVM localization. Of the seven GFP-tagged proteins,
three proteins were clearly localized to the PVM during liver stage development
(Fig. 4). These were the serine/threonine phosphatase UIS2 (PBANKA_1328000) and
two conserved Plasmodium proteins with unknown function (PBANKA_0519300 and
PBANKA_0509000). During blood stage development, UIS2-GFP mainly surrounded
developing merozoites as a whole, while free merozoites were not enclosed by a UIS2
signal, suggesting that the peripheral staining in developing schizonts is derived from
PVM localization of the protein during blood stage development. In line with this, UIS2
was found to colocalize with EXP1 in liver stage parasites, indicating PVM localization
also during this stage of development (Fig. 4A). The GFP signal of PBANKA_0519300 in
infected RBCs was found at the parasite periphery and between forming merozoites,
pointing to localization of this protein in the PV or PPM and maybe additionally to the
PVM. Free merozoites of this parasite line were not surrounded by a GFP signal,
excluding PPM localization and suggesting that PBANKA_0519300 is localized to the PV
and possibly additionally to the PVM during blood stage development. In liver stage
parasites, PBANKA_0519300 localized to the PVM, as conﬁrmed by colocalization with
EXP1 (Fig. 4B). PBANKA_0509000 showed weak, hazy staining within the parasite
cytoplasm in blood stage parasites; however, it partially colocalized with EXP1 in liver
stage cytomeres (Fig. 4C), demonstrating that this protein can be transported to the
PVM during parasite development also.
Candidate proteins with PV/PPM or other localizations. Two other conserved Plas-
modium proteins with unknown functions (PBANKA_0519400 and PBANKA_0519200)
were found mainly in the PV or PPM during blood and liver stage development (Fig. 5).
PBANKA_0519400 surrounded developing blood stage merozoites individually, while
no GFP signal was found around free merozoites, pointing to PV localization of this
protein during blood stage development. Similarly, in liver stage cytomeres, the protein
did not colocalize with EXP1 and instead showed a typical PV/PPM localization (Fig. 5A).
To investigate this further, we performed colocalization analysis with the PPM marker
protein merozoite surface protein 1 (MSP1). PBANKA_0519400 colocalized with MSP1
only partially and concentrated at the parasite periphery of late liver stage parasites,
which is consistent with PV localization also during liver stage development (Fig. S4).
The other protein, PBANKA_0519200, also surrounded developing merozoites individ-
ually; however, free merozoites of this parasite line were clearly surrounded by a GFP
signal, indicating PPM localization of this protein in blood stage parasites. During liver
stage development, PBANKA_0519200 did not colocalize with EXP1 and showed typical
PV/PPM localization (Fig. 5B). Costaining with PPM marker MSP1 showed partial colo-
calization with this protein, especially in liver stage merozoites. PBANKA_0519200 also
concentrated at the parasite periphery during liver stage development, indicating
that this protein localizes additionally to the PV during that stage of development
(Fig. S5).
Another conserved Plasmodium protein with unknown function (PBANKA_0924800)
showed one single focus per parasite in developing and free blood stage merozoites,
suggesting a secretory pathway or invasion organelle location. During liver stage
development, the protein also appeared as discrete foci in cytomere stage parasites,
indicating localization similar to that observed in blood stage parasites (Fig. 6A). Finally,
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a Plasmodium exported protein (PHIST) with unknown function (PBANKA_1229000) was
exported to the host cell cytosol in developing merozoites, while no signal was
observed in free merozoites. In the cytomere stage of liver stage parasites, this protein
was also secreted by the parasite but mainly localized to the PV (Fig. 6B).
FIG 4 Candidates with a PVM localization. Live-cell microscopy images of developing blood stage merozoites
(upper panels) or free blood stage merozoites (middle panels) as well as an IFA of ﬁxed liver stage cytomeres
stained with an antiserum against EXP1 (lower panels) are shown for parasites expressing endogenously GFP-
tagged PBANKA_1328000 (A), PBANKA_0519300 (B), or PBANKA_0509000 (C). The endogenously GFP-tagged
proteins are shown in green, the cytosolic mCherry proteins are shown in red, and the EXP1 signal in the IFA of
ﬁxed liver stage parasites is displayed in purple. DNA of Hoechst- or DAPI-stained nuclei is shown in blue. DIC,
differential interference contrast. Scale bars for all blood stages; 2 m; scale bars for the liver stage, 10 m.
BioID of the Plasmodium PVM
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DISCUSSION
During their development within RBCs and hepatocytes, Plasmodium parasites are
surrounded by a PVM. This membrane represents the interphase between parasite and
host and plays a fundamental role in its interaction with the host cell. In this study, we
used BioID in combination with endogenous GFP tagging to identify novel PVM
proteins in P. berghei.
On the basis of our two BioID experiments, we obtained a list of 61 candidate
proteins that were potentially localized to the blood stage PVM. Many of these, such as
all components of the PTEX complex, were already known to be localized to this
compartment. In general, this conﬁrms the good coverage of our approach. However,
a considerable number of the 61 candidate proteins are known not to locate to the
PVM, which was evident in the endogenous GFP-tagging approach of this study as well,
where four of the seven analyzed proteins were found in other non-PVM compartments
such as the PV or the PPM. This occurrence of quite a high number of off-target hits
might have derived from the fact that the EXP1-BirA*-V5 fusion protein is already active
during its transport through the secretory pathway. During this transport the PPM and
the PV have to be crossed and proteins of these compartments as well as other proteins
FIG 5 Candidates that are localized to the PV and/or PPM. Live-cell microscopy images of developing blood stage
merozoites (upper panels) or free blood stage merozoites (middle panels) as well as an IFA of ﬁxed liver stage
cytomeres stained with an antiserum against EXP1 (lower panels) are shown for parasites expressing endogenously
GFP-tagged PBANKA_0519400 (A) and PBANKA_0519200 (B). The endogenously GFP-tagged proteins are shown in
green, the cytosolic mCherry proteins are shown in red, and the EXP1 signal in the IFA of ﬁxed liver stage parasites
is displayed in purple. DNA of Hoechst- or DAPI-stained nuclei is shown in blue. DIC, differential interference
contrast. Scale bars for all blood stages, 2 m; scale bars for the liver stage, 10 m.
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of the secretory pathway might become biotinylated. Furthermore, we currently cannot
completely exclude the possibility that the constitutive expression of EXP1 driven by
the strong P. berghei eef1 promoter or its fusion to the BirA*-V5 protein might interfere
with the proper targeting of EXP1 to the PVM. Possibly, this could lead to partial PV
localization of the EXP1-BirA* fusion protein, which could biotinylate proteins not only
of the PVM but also of the PV and PPM there.
Rather than an in-depth analysis of single candidate proteins, we used endogenous
GFP tagging for analysis of seven candidate genes during blood and liver stage
development as a proof of concept for our BioID approach. This analysis resulted in the
identiﬁcation of three previously unknown proteins of the liver stage PVM, which were
the serine/threonine protein phosphatase UIS2 and two conserved Plasmodium pro-
teins with unknown functions (PBANKA_0519300 and PBANKA_0509000).
UIS2 was initially discovered in a screen for genes that display upregulated expres-
sion in salivary gland sporozoites (20) and has been shown to be essential for blood
stage development in P. berghei and P. falciparum (21, 22). Similarly to our results
obtained in this study, UIS2 also localizes to the PVM of P. falciparum blood stage
FIG 6 Localization of PBANKA_1229000 and PBANKA_0924800 during blood and liver stage development. Live-cell
microscopy images of developing blood stage merozoites (upper panels) or free blood stage merozoites (middle
panels) as well as an IFA of ﬁxed liver stage cytomeres stained with an antiserum against EXP1 (lower panels) are
shown for parasites expressing endogenously GFP-tagged PBANKA_1229000 (A) and PBANKA_0924800 (B). The
endogenously GFP-tagged proteins are shown in green, the cytosolic mCherry proteins are shown in red, and the
EXP1 signal in IFAs of ﬁxed liver stage parasites is displayed in purple. DNA of Hoechst- or DAPI-stained nuclei is
shown in blue. DIC, differential interference contrast. Scale bars for all blood stages, 2 m; scale bars for the liver
stage, 10 m.
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parasites (22). It is interesting that the localization of UIS2 in P. berghei blood stages is
slightly more diffuse than its localization in P. falciparum, which might be due to
strain-speciﬁc differences in expression. By utilization of a conditional knockout ap-
proach, Zhang and colleagues provided evidence that UIS2 plays a role in transforma-
tion of P. berghei sporozoites to liver stages through a function in dephosphorylating
eIF2-P in the parasite cytoplasm (21). In this regard, our observation that UIS2 localizes
to the PVM during blood and liver stage development is very interesting, as it indicates
that UIS2 might have another noncytoplasmic and yet-to-be-identiﬁed function in PVM
biology.
The other two novel proteins of the liver stage PVM, PBANKA_0519300 and
PBANKA_0509000, were both shown to be nonessential for blood stage development
in P. berghei (23, 24), but the function of these two proteins during liver stage
development has not been analyzed so far. The P. falciparum ortholog of PBANKA_
0509000, which was recently named EXP3, was localized to the blood stage PVM as well
(22, 24). Remarkably, although likely not essential for P. falciparum blood stage devel-
opment, EXP3 was shown to be part of a newly described exported protein-interacting
complex (EPIC), which has been proposed to be involved in the trafﬁcking of virulence
determinants to the surface of the infected erythrocyte (24). Thus, the fact that we did
localize the P. berghei ortholog of EXP3 to the liver stage PVM also is intriguing, as this
suggests that an EPIC-like complex could also be involved in trafﬁcking of parasite
proteins to the infected hepatocyte, a hypothesis which clearly needs further investi-
gation.
In this study, we used the promiscuous biotin ligase BirA* to identify novel proteins
of the Plasmodium PVM. A very promising approach for the future might be the
application of the engineered enzyme ascorbate peroxidase (APEX). This enzyme can
also be fused to a protein of interest and, similarly to BirA*, can lead to biotinylation of
nearby proteins, with the big difference of having a labeling time of 1 min, which is
much shorter than the many hours of labeling time which are needed to achieve
satisfactory biotinylation levels in a BioID experiment (25). The temporal speciﬁcity of
the biotinylation reaction could thus be increased, and it might become possible to
look at the stage-speciﬁc proteome of the PVM and to speciﬁcally identify proteins
involved in PVM remodeling early in infection or to identify PVM-localized proteins
involved in membrane disruption processes of late stage parasites during egress from
host cells.
The BioID technique has become a powerful and widely used tool in cell biology and
has already been applied in studies of several parasite species, including Trypanosoma
brucei (26), Toxoplasma gondii (27–29), and P. falciparum (22). It has been used in
P. berghei studies in an in vivo setting, where the biotinylation reaction was carried out
in parasite-infected mice (30). Here, we show for the ﬁrst time the successful application
of BioID in in vitro-cultivated P. berghei blood stage parasites and demonstrate its
usefulness in identiﬁcation of novel proteins of the Plasmodium PVM, altogether
contributing to our understanding of the molecular makeup of this fascinating interface
between a parasite and its host cell.
MATERIALS AND METHODS
Ethics statement. All experiments performed were conducted in strict accordance with the guide-
lines of the Swiss Tierschutzgesetz (TSchG; Animal Rights Laws) and approved by the ethical committee
of the University of Bern (permit number BE109/13).
Experimental animals. BALB/c mice used in the experiments were between 6 and 10 weeks of age
and were from Harlan Laboratories or Charles River, Inc., or were bred in the central animal facility at the
University of Bern. Mosquito feeds were performed on anesthetized mice (Ketavet/Domitor), and all
efforts were made to minimize suffering.
Mosquito infection. Infection with P. berghei parasites was initiated by intraperitoneal injection of
blood stabilates. After a parasitemia level of 4% was reached, 40 l of infected blood (mixed with 160 l
of phosphate-buffered saline [PBS]) was injected intravenously into mice that had been pretreated with
an intraperitoneal injection of 200 l phenylhydrazine (6 mg/ml in PBS) 2 to 4 days prior to infection. At
three to four days after infection, mice with a parasitemia level of at least 7% were anesthetized for 1 h
to allow feeding of 150 female Anopheles stephensimosquitoes. Mosquitoes were kept at 20.5°C with 80%
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humidity, and for infection experiments, sporozoites were isolated from infected salivary glands 16 to
27 days post-blood meal.
Culture and infection of HepG2 cells with P. berghei. HepG2 cells (obtained from the European
Cell Culture Collection) were cultured as described previously (31). For infection, 5  104 cells were
seeded in 24-well plates with coverslips. The next day, P. berghei sporozoites were isolated from salivary
glands of infected A. stephensi mosquitoes and added to HepG2 cells in culture medium additionally
containing 2.5 g/ml amphotericin B (PAA Laboratories). After an incubation period of 2 h, the
sporozoite-containing medium was removed and fresh infection medium was added. Subsequently,
medium was changed once per day.
Cloning of DNA constructs. All PCRs were performed using Phusion DNA polymerase (NEB). PCR
products were routinely cloned into pJET1.2 (Fermentas) and conﬁrmed by sequencing (Microsynth). The
pL0017-CEXP1-BirA*-V5 plasmid was generated by ﬁrst amplifying the BirA* coding sequence from
pcDNA3.1-mycBioID (17) using primers BirA-V5-fw and BirA-V5-rev, whereby a V5 tag was added to the
C-terminal end of BirA*. The PCR product was then cloned into pL0017 (32) using BamHI and XbaI
restriction sites. Subsequently, the EXP1 coding sequence was ampliﬁed from blood stage cDNA using
primers EXP1-fw and EXP1-rev and cloned in frame with BirA*-V5 into the pL0017 vector using BamHI
and NotI restriction sites. To generate the plasmids for C-terminal endogenous GFP tagging of PVM
candidates, the C-terminal homology regions of the candidate genes were ampliﬁed by PCR and cloned
in frame with GFP into pOB277 (18) using KpnI and ApaI restriction sites. All primer sequences are listed
in Table S3 in the supplemental material.
Transfection of P. berghei parasites and conﬁrmation of correct integration. The pL0017-CEXP1-
BirA*-V5 plasmid and the pOB277-based GFP-tagging vectors were linearized using the restriction
enzymes listed in Table S4. Linearized plasmids were transfected into blood stage schizonts of P. berghei
ANKA mCherryHsp70 parasites (16) using standard methods of transfection (33). Transfected parasites
were selected by supplementing the drinking water of infected mice with pyrimethamine (Sigma).
Parasite genomic DNA was isolated from 0.05% saponin-treated infected red blood cells using a
NucleoSpin Blood QuickPure kit (Macherey-Nagel), and successful integration of the plasmid into the
genome was conﬁrmed by diagnostic PCR using GoTaq Flexi DNA polymerase (Promega). All primer
sequences are listed in Table S3.
Live-cell imaging and immunoﬂuorescence assay. Blood stage parasites from schizont cultures or
from a drop of tail blood were imaged live, and, for visualization of DNA, 1 g/ml Hoechst 33342 (Sigma)
was added. Blood stage IFA was performed as described previously (19). Primary antibodies were rat
anti-red ﬂuorescent protein (anti-RFP) (Chromotek) and mouse anti-V5 (Invitrogen). As secondary anti-
bodies, donkey anti-rat Alexa Fluor 594 (Invitrogen) and goat anti-mouse Cy5 (Dianova) were used.
Streptavidin-Alexa Fluor 488 (Invitrogen) and 1 g/ml DAPI (4=,6-diamidino-2-phenylindole) (Sigma) were
applied together with the secondary antibodies, and coverslips were mounted using Dako ﬂuorescent
mounting medium (Dako). All blood stage images were taken on a Leica DM5500 B epiﬂuorescence
microscope using an HCX Plan-Apochromat 100/1.4 oil objective, and image processing was performed
using ImageJ.
For liver stage IFA, 5  104 HepG2 cells were seeded onto coverslips in 24-well plates and infected
the following day with P. berghei sporozoites. At different time points postinfection, cells were ﬁxed with
4% paraformaldehyde (PFA)–PBS for 20 min at room temperature, followed by permeabilization per-
formed with ice-cold methanol for at least 30 min. Nonspeciﬁc binding sites were blocked by incubation
in 10% fetal calf serum (FCS)–PBS, followed by incubation with primary antibodies (rabbit anti-GFP
[Invitrogen] and chicken anti-EXP1 and rat anti-MSP1 [both generated at the Bernhard Nocht Institute,
Hamburg, Germany]) and subsequently with ﬂuorescently labeled secondary antibodies (goat anti-rabbit
Alexa Fluor 488 [Invitrogen], goat anti-rat Alexa Fluor 647 [Invitrogen], and donkey anti-chicken Cy5
[Dianova]) diluted in 10% FCS–PBS. DNA was stained with 1 g/ml DAPI. Labeled cells were mounted on
microscope slides with Dako ﬂuorescent mounting medium and analyzed by using a Leica TCS SP8
confocal microscope with an HC PL 100/1.40 oil objective. Image processing was performed using
ImageJ.
Western blotting. Western blotting was performed as described previously (34) using rat anti-RFP
(Chromotek) and mouse anti-V5 (Invitrogen) as primary antibodies. Goat anti-rat IgG 680LT IRDye and
goat anti-mouse IgG 680LT IRDye (both Li-COR) were used as secondary antibodies. Biotinylated proteins
were detected using IRDye 800CW-labeled streptavidin (Li-COR).
BioID of PVM proteins. Infection with EXP1-BirA*-V5 and WT mCherryHsp70 parasites was initiated by
intraperitoneal injection of blood stabilates into two mice per parasite line. After a parasitemia level of
3% to 4% was reached, mice were sacriﬁced and blood was removed by cardiac puncture and incubated
in an overnight schizont culture as previously described (33). Incubation was done for 18 h in the
presence or absence of 150 M biotin (Sigma). Schizonts were enriched on a Nycodenz gradient, and a
small sample was taken for Western blotting as described above. Detergent-based extraction and afﬁnity
capture of biotinylated proteins were basically done as described before (27); however, incubation on
streptavidin Mag Sepharose beads (GE Healthcare) was done at 4°C overnight with continuous agitation.
Mass spectrometric analysis. Mass spectrometric analysis was performed by the proteomics and
mass spectrometry core facility at the Department of Biomedical Research of the University of Bern.
Proteins were reduced, alkylated, and digested with trypsin for 6 h at 37°C on beads. Digests were loaded
onto a precolumn (PepMap C18) (5-m pore size; 300 A; 300-m inner diameter [i.d.] by 15-mm length)
at a ﬂow rate of 20 l/min with solvent A (0.1% formic acid–water/acetonitrile [98:2]). After loading,
peptides were eluted in back ﬂush mode onto the analytical nanocolumn (C18) (5-m pore size; 300 A;
0.075-mm i.d. by 150-mm length) using an acetonitrile gradient of 5% to 40% solvent B (0.1% formic
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acid–water/acetonitrile [4.9:95]) for 40 min at a ﬂow rate of 400 nl/min. The column efﬂuent was directly
coupled to a Fusion Lumos mass spectrometer (Thermo Fischer) via a nanospray electrospray ionization
(ESI) source. Data acquisition was made in data-dependent mode with precursor ion scans recorded in
a Fourier transform detector (FT) with a resolution of 120,000 (at m/z  400) parallel to top-speed
fragment spectra of the most intense precursor ions in the linear trap for a maximum cycle time of 3 s.
Protein identiﬁcation and label-free quantitation. Raw ﬁles were converted to mzXML format with
ProteoWizard v3.0.6002 (http://proteowizard.sourceforge.net/), searched with comet (v2015.01) (35)
against a combined P. berghei sequence database consisting of data from http://www.uniprot.org and
http://plasmodb.org/plasmo/ (PlasmoDB-28) (with the following parameters: fully tryptic, 2 missed
cleavages allowed, 20 ppm precursor mass tolerance, ﬁxed carbidomethylated cysteines, variable mod-
iﬁcation on methionines), and further processed with the transproteomic pipeline (TPP; v4.7) (36) to
obtain identiﬁed peptides and a protein list at the false-discovery rate of 1%. Liquid chromatography-
tandem mass spectrometry (LC-MS/MS) runs were aligned and precursor intensities were calculated in
ProgenesisQI (Nonlinear Dynamics, v2). Protein abundances and signiﬁcant results of testing EXP1-
BirA*-V5 versus WT parasites were calculated with MSstats (v3.2.2) (37) based on ANOVA models for each
replicate separately. P values were adjusted according to the method of Benjamini and Hochberg. Only
proteins with at least two independent peptide measurements were taken into account. Proteins with
fold change values of at least 3 versus wild-type results and an adjusted P value of below 0.05 in both
biological replicates were regarded as signiﬁcantly enriched in EXP1-BirA*-V5 parasites.
Data availability. All data generated or analyzed during this study are included in this published
article (and its supplemental material ﬁles). The mass spectrometry proteomics data have been deposited
into the ProteomeXchange Consortium via the PRIDE partner repository (38) with data set identiﬁer
PXD007857.
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